Laurence Sperling is a Cardiology physician affiliated with Emory University. OpenAlex indexes 556 publications with 34,358 citations (h-index 69); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NovartisProgram year20251 paymentResearch$4,337
- RegeneronProgram year20251 paymentResearch$1,821
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20221 payment$50
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
87.8%Statin25.1%Atorvastatin Calcium50%Rosuvastatin Calcium34%Pravastatin Sodium12%Simvastatin5%Part D<11 patientsBeta blocker17.3%Carvedilol46%Metoprolol Succinate36%Metoprolol Tartrate18%Part D≥46 patients+ 11 more classes in this area
Blood & clotting
10.2%Factor Xa inhibitor7.4%Eliquis100%Part D≥37 patientsP2Y12 inhibitor2.8%Clopidogrel100%Part D≥20 patientsMetabolism & gastrointestinal
2%Potassium supplement1.1%Potassium Chloride100%Part D<11 patientsSGLT2 inhibitor1%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
JAMA Internal Medicine
2024 - Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Allan Levey, MD
Emory University
Craig Coopersmith, MD
Emory University
James Lah, MD
Emory University
Vasilis Babaliaros, MD
Emory University
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Gregg Fonarow, MD
Ronald Reagan UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”